Trial Profile
A 48-week study to evaluate efficacy and safety of ME3738 in combination with PEG IFN-α-2a in naive chronic hepatitis C virus genotype 1 patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Nov 2015
Price :
$35
*
At a glance
- Drugs ME 3738 (Primary) ; Peginterferon alfa-2a
- Indications Hepatitis C
- Focus Therapeutic Use
- 28 Nov 2015 New trial record